Moreover, a reverse genetic screen study has demonstrated that reduction of reactivated CRAF induced by MEK1/2 inhibitors enlarges the clinical benefit of the latter in KRAS mutant colorectal cancer (CRC) cell lines.17 Here, KRAS is linked to colorectal cancer.